MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA). The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637. This highly potent compound has demonstrated antiviral activity in preclinical studies in both prophylaxis and treatment, and was generally well tolerated in multiple adult volunteer Phase I studies. MicroDose plans to develop the newly acquired compound in dry powder format for inhalation via MicroDose’s novel dry powder inhaler (DPI).
